These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28748718)

  • 41. Pharmacogenetics of metformin response: a step in the path toward personalized medicine.
    Reitman ML; Schadt EE
    J Clin Invest; 2007 May; 117(5):1226-9. PubMed ID: 17476355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis.
    Phung OJ; Baker WL; Tongbram V; Bhardwaj A; Coleman CI
    Ann Pharmacother; 2012 Apr; 46(4):469-76. PubMed ID: 22474136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
    Tseng CH
    Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Trends Pharmacol Sci; 2012 Jun; 33(6):312-22. PubMed ID: 22475684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pitfalls in treatment with oral antidiabetic agents].
    Perusicová J
    Vnitr Lek; 1998 Jan; 44(1):30-5. PubMed ID: 9750481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antidiabetic drugs and risk of cancer.
    Tokajuk A; Krzyżanowska-Grycel E; Tokajuk A; Grycel S; Sadowska A; Car H
    Pharmacol Rep; 2015 Dec; 67(6):1240-50. PubMed ID: 26481548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opposing Effects of Antidiabetic Interventions on Malignant Growth and Metastasis.
    Tschöp MH; Stumvoll M; Ristow M
    Cell Metab; 2016 Jun; 23(6):959-960. PubMed ID: 27304493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Editorial: The relationship between diabetes and cancers and its underlying mechanisms.
    Huo Q; Wang J; Zhang N; Xie L; Yu H; Li T
    Front Endocrinol (Lausanne); 2022; 13():992569. PubMed ID: 36017321
    [No Abstract]   [Full Text] [Related]  

  • 50. Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes.
    Salvo F; Faillie JL
    Therapie; 2019 Apr; 74(2):255-260. PubMed ID: 30470475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New use of prescription drugs prior to a cancer diagnosis.
    Pottegård A; Hallas J
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):223-227. PubMed ID: 27889931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them.
    Siltari A; Auvinen A; Murtola TJ
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572236
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs.
    Olatunde A; Nigam M; Singh RK; Panwar AS; Lasisi A; Alhumaydhi FA; Jyoti Kumar V; Mishra AP; Sharifi-Rad J
    Cancer Cell Int; 2021 Sep; 21(1):499. PubMed ID: 34535145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Zuellig Pharma Korea Consortium Database: An on-site drug wholesales database for pharmacoepidemiological studies using real-world data
.
    Jeong HE; Oh IS; Li J; Vilfeu E; Ryuu SA; Shin JY
    Int J Clin Pharmacol Ther; 2019 Sep; 57(9):445-449. PubMed ID: 31262397
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer biology in diabetes.
    Sen S; He Y; Koya D; Kanasaki K
    J Diabetes Investig; 2014 May; 5(3):251-64. PubMed ID: 24843770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Letter to the Editor: Novel antidiabetic drugs and the risk for HCC. What else to expect from these "wonderful" drug classes?
    Patoulias D
    Hepatology; 2023 Jun; 77(6):E183. PubMed ID: 36724447
    [No Abstract]   [Full Text] [Related]  

  • 57. Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis.
    Cheung B; Fei Y; Tsoi MF
    Eur Cardiol; 2020 Feb; 15():e40. PubMed ID: 32612700
    [No Abstract]   [Full Text] [Related]  

  • 58. Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.
    Filippatos T; Tzavella E; Rizos C; Elisaf M; Liamis G
    Expert Opin Drug Saf; 2017 Oct; 16(10):1121-1132. PubMed ID: 28748724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity.
    Böhm A; Wagner R; Machicao F; Holst JJ; Gallwitz B; Stefan N; Fritsche A; Häring HU; Staiger H
    PLoS One; 2017; 12(7):e0181880. PubMed ID: 28750074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.